Lidder Alcina K, Detwiller Kara Y, Price Caroline P E, Kern Robert C, Conley David B, Shintani-Smith Stephanie, Welch Kevin C, Chandra Rakesh K, Peters Anju T, Grammer Leslie C, Man Li-Xing, Schleimer Robert P, Tan Bruce K
University of Rochester School of Medicine and DentistryUniversity of Rochester Medical Center, Rochester, NY.
Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Int Forum Allergy Rhinol. 2017 Feb;7(2):128-134. doi: 10.1002/alr.21866. Epub 2016 Nov 7.
Responsiveness, or sensitivity to clinical change, is important when selecting patient-reported outcome measures (PROMs) for research and clinical applications. This study compares responsiveness of PROMs used in chronic rhinosinusitis (CRS) to inform the future development of a highly responsive instrument that accurately portrays CRS patients' symptom experiences.
Adult CRS patients initiating medical therapy (MT; n = 143) or undergoing endoscopic sinus surgery after failing MT (ESS; n = 123) completed the 22-item Sino-Nasal Outcome Test (SNOT-22), European Position Statement on Rhinosinusitis (EPOS) visual analog scale (VAS), and 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) at baseline and 3 months after treatment. Cohen's d and paired t statistics were used to evaluate the responsiveness of each measure.
Fifty-two (36.4%) subjects and 42 (34.1%) subjects in the MT and ESS groups, respectively, completed baseline and 3-month questionnaires. Subjects with and without 3-month data were similar with respect to baseline demographics, VAS scores, and SNOT-22 scores (p > 0.05). In MT patients, CRS-specific measures, like VAS (d = -0.58, p < 0.01; t = -1.81, p > 0.05) and SNOT-22 (d = -0.70, p < 0.01; t = -3.29, p < 0.05) scores, were more responsive than PROMIS-29 general health domains (p > 0.05 for Cohen's d). In ESS patients, VAS (d = -1.97; t = -9.63, both p < 0.01) and SNOT-22 (d = -1.56; t = -9.99, both p < 0.01) scores were similarly more responsive, although changes in PROMIS-29 domains of Fatigue (d = -0.82, p = 0.01; t = -4.63, p < 0.01), Sleep Disturbance (d = -0.83; t = -3.77, both p < 0.01), and Pain Intensity (d = -1.0; t = -5.67, both p < 0.01) were significant. All 22 individual SNOT-22 items differed significantly after surgery, whereas only 8 items were consistently responsive after MT.
For both MT and ESS patients, CRS-specific PROMs are more responsive to posttreatment clinical changes than general health measures. Still, the SNOT-22 contains items that likely decrease its overall responsiveness. Our findings also indicate that existing PROMs had a greater response to ESS than MT.
在为研究和临床应用选择患者报告结局指标(PROMs)时,反应性,即对临床变化的敏感性,非常重要。本研究比较了慢性鼻-鼻窦炎(CRS)中使用的PROMs的反应性,以为未来开发一种能准确描述CRS患者症状体验的高反应性工具提供参考。
开始药物治疗(MT;n = 143)或药物治疗失败后接受鼻内镜鼻窦手术(ESS;n = 123)的成年CRS患者在基线和治疗后3个月完成了22项鼻-鼻窦结局测试(SNOT-22)、欧洲鼻窦炎立场声明(EPOS)视觉模拟量表(VAS)和29项患者报告结局测量信息系统(PROMIS-29)。使用科恩d值和配对t统计量来评估每个指标的反应性。
MT组和ESS组分别有52名(36.4%)和42名(34.1%)受试者完成了基线和3个月的问卷调查。有和没有3个月数据的受试者在基线人口统计学、VAS评分和SNOT-22评分方面相似(p > 0.05)。在MT患者中,CRS特异性指标,如VAS(d = -0.58,p < 0.01;t = -1.81,p > 0.05)和SNOT-22(d = -0.70,p < 0.01;t = -3.29,p < 0.05)评分,比PROMIS-29一般健康领域更具反应性(科恩d值p > 0.05)。在ESS患者中,VAS(d = -1.97;t = -9.63,两者p < 0.01)和SNOT-22(d = -1.56;t = -9.99,两者p < 0.01)评分同样更具反应性,尽管PROMIS-29疲劳领域(d = -0.82,p = 0.01;t = -4.63,p < 0.01)、睡眠障碍(d = -0.83;t = -3.77,两者p < 0.01)和疼痛强度(d = -1.0;t = -5.67,两者p < 0.01)的变化也很显著。所有22项SNOT-22单项在手术后均有显著差异,而MT后只有8项持续有反应。
对于MT和ESS患者,CRS特异性PROMs比一般健康指标对治疗后临床变化更具反应性。尽管如此,SNOT-22中的一些项目可能会降低其整体反应性。我们的研究结果还表明,现有PROMs对ESS的反应比对MT的反应更大。